Bausch Health Cos (NYSE:BHC) Stock Gets Downgrade from Zacks Research

Posted by Francis Steltz on Nov 7th, 2026

Bausch Health Cos (NYSE:BHC – Get Free Report) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Thursday, Zacks reports.

BHC has been the topic of several other research reports. Royal Bank Of Canada upped their price objective on shares of Bausch Health Cos from $9.00 to $10.00 and gave the stock a “sector perform” rating in a report on Thursday, October 29th. Jefferies Financial Group lifted their price target on Bausch Health Cos from $6.50 to $8.00 and gave the company a “hold” rating in a research note on Thursday, October 29th. Weiss Ratings reissued a “sell (d)” rating on shares of Bausch Health Cos in a research report on Thursday, October 29th. Finally, Wall Street Zen upgraded Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Six investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $8.25.

Check Out Our Latest Research Report on BHC

Bausch Health Cos Stock Up 3.0%

Shares of NYSE:BHC opened at $8.20 on Thursday. The business has a 50-day moving average price of $6.40 and a 200-day moving average price of $5.74. The stock has a market cap of $3.07 billion, a price-to-earnings ratio of -3.58 and a beta of 0.30. Bausch Health Cos has a 52-week low of $4.33 and a 52-week high of $9.04.

Bausch Health Cos (NYSE:BHC – Get Free Report) last issued its earnings results on Wednesday, October 28th. The company reported $1.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.25 by $0.52. The business had revenue of $2.90 billion during the quarter, compared to the consensus estimate of $2.72 billion. Bausch Health Cos had a negative return on equity of 401.73% and a negative net margin of 7.57%. As a group, equities analysts anticipate that Bausch Health Cos will post 4.53 EPS for the current fiscal year.

Insider Buying and Selling at Bausch Health Cos

In other Bausch Health Cos news, insider Aimee Lenar sold 36,827 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $7.03, for a total transaction of $258,893.81. Following the completion of the sale, the insider directly owned 334,853 shares of the company’s stock, valued at $2,354,016.59. This represents a 9.91% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 20.67% of the company’s stock.

Institutional Trading of Bausch Health Cos

Hedge funds and other institutional investors have recently made changes to their positions in the business. Paulson & CO. Inc. acquired a new position in Bausch Health Cos in the 2nd quarter valued at about $361,151,000. Royal Bank of Canada lifted its holdings in shares of Bausch Health Cos by 24.9% during the first quarter. Royal Bank of Canada now owns 11,363,498 shares of the company’s stock valued at $61,362,000 after purchasing an additional 2,262,894 shares in the last quarter. MFN Partners Management LP purchased a new position in Bausch Health Cos in the 2nd quarter worth approximately $29,580,000. Dimensional Fund Advisors LP boosted its position in Bausch Health Cos by 10.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,604,818 shares of the company’s stock valued at $19,456,000 after buying an additional 350,823 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in shares of Bausch Health Cos by 10.0% in the first quarter. Renaissance Technologies LLC now owns 1,575,772 shares of the company’s stock worth $8,509,000 after buying an additional 143,581 shares during the last quarter. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Cos Company Profile

(Get Free Report)

Bausch Health Companies Inc (NYSE:BHC) is a multinational specialty pharmaceutical company focused on developing, manufacturing and commercializing branded, generic and over-the-counter medicines. Its portfolio serves several therapeutic areas, including gastroenterology, dermatology, neurology, ophthalmology, hospital products and other specialty-care markets.

The company markets products through businesses such as Salix Pharmaceuticals, Ortho Dermatologics, Solta Medical and its international pharmaceutical operations.